MedTrace Logo

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

NCT03695978 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-11-10

No results posted yet for this study

Summary

International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.

Conditions

  • Haemophilia A

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Principal Investigators

  • Sigurd Knaub, PhD · Octapharma

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-13
Primary Completion
2030-06-30
Completion
2030-06-30

Countries

  • United States
  • Argentina
  • Azerbaijan
  • Belarus
  • Belgium
  • Canada
  • Croatia
  • Estonia
  • France
  • Germany
  • Hungary
  • Italy
  • Lithuania
  • Mexico
  • Russia
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03695978 on ClinicalTrials.gov